Using the Food and Drug Administration´s Sentinel System for surveillance of TB infection

BACKGROUND: We examined patterns in care for individuals treated for latent TB infection (LTBI) in the US Food and Drug Administration´s Sentinel System.METHODS: Using administrative claims data, we identified patients who filled standard LTBI treatment prescriptions during 2008-2019. In these cohor...

Full description

Saved in:
Bibliographic Details
Published in:The international journal of tuberculosis and lung disease 2022-12, Vol.26 (12), p.1170-1176
Main Authors: Walker, W. L., Schmit, K. M., Welch, E. C., Vonnahme, L. A., Talwar, A., Nguyen, M., Stojanovic, D., Langer, A. J., Cocoros, N. M.
Format: Article
Language:English
Subjects:
Administrative Claims Data
Antitubercular Agents - administration & dosage
Drug Prescriptions - statistics & numerical data
Humans
Infections
Isoniazid
Isoniazid - administration & dosage
Patients
prescription-based cohort, LTBI
Rifampin
Rifampin - administration & dosage
Sentinel system
Treatment Completion
Tuberculosis
Tuberculosis - diagnosis
Tuberculosis - epidemiology
United States
United States Food and Drug Administration
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: We examined patterns in care for individuals treated for latent TB infection (LTBI) in the US Food and Drug Administration´s Sentinel System.METHODS: Using administrative claims data, we identified patients who filled standard LTBI treatment prescriptions during 2008-2019. In these cohorts, we assessed LTBI testing, clinical management, and treatment duration.RESULTS: Among 113,338 patients who filled LTBI prescriptions, 80% (90,377) received isoniazid (INH) only, 19% (21,235) rifampin (RIF) only, and 2% (1,726) INH + rifapentine (RPT). By regimen, the proportion of patients with documented prior testing for TBI was 79%, 54%, and 91%, respectively. Median therapy duration was 84 days (IQR 35-84) for the 3-month once-weekly INH + RPT regimen, 60 days (IQR 30-100) for the 6- to 9-month INH regimen, and 30 days (IQR 2-60) for the 4-month RIF regimen.CONCLUSIONS: Among the cohorts, INH-only was the most commonly prescribed LTBI treatment. Most persons who filled a prescription for LTBI treatment did not have evidence of completing recommended treatment duration. These data further support preferential use of shorter-course regimens such as INH + RPT.
ISSN:1027-3719
1815-7920
1815-7920
DOI:10.5588/ijtld.22.0259